ABVC BioPharma Selects Additional Vitargus® Phase II Study Site
New Australia Site Confirmed to Participate in the Study
FREMONT, CA, Sept. 09, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced a new clinical site in Australia has been selected to participate in the Phase II clinical study of Vitargus®, the first bio-degradable vitreous substitute to facilitate retina re-attachment surgery. The new site, located at the Sydney Eye Hospital in Sydney, New South Wales, will join East Melbourne Eye Group in East Melbourne, Victoria, Australia and Ramathibodi Hospital and Srinagarind Hospital in Thailand, to participate in the study.
Related news for (ABVC)
- Breaking News: MoBot’s Latest Update as of 04/07/25 10:00 AM
- MoBot’s Stock Market Highlights – 04/01/25 10:00 AM
- MoBot alert highlights: NASDAQ: EDIT, NASDAQ: EDBL, NASDAQ: GCL, NASDAQ: ABVC, NASDAQ: SRM (02/18/25 10:00 AM)
- ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21
- ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners